enGene Therapeutics (ENGN)
Market Price (7/13/2026): $1.905 | Market Cap: $132.8 MilSector: Health Care | Industry: Biotechnology
enGene Therapeutics (ENGN)
Market Price (7/13/2026): $1.905Market Cap: $132.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -170% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -161% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -133 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -100% High stock price volatilityVol 12M is 123% Key risksENGN key risks include [1] a near-total reliance on the success of its single product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -170% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -161% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -133 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -100% |
| High stock price volatilityVol 12M is 123% |
| Key risksENGN key risks include [1] a near-total reliance on the success of its single product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
enGene Therapeutics (ENGN) stock has lost about 70% since 3/31/2026 because of the following key factors:
1. Disappointing 12-Month Durability Data from LEGEND Trial. enGene Therapeutics announced updated interim results from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid on May 7, 2026. While initial complete response (CR) rates were reported at 54% at any time and 43% at six months, the crucial Kaplan-Meier estimate for the 12-month CR rate was only 25%. This significantly lower durability outcome, which the CEO acknowledged was "not what we hoped," raised substantial concerns among investors regarding the long-term efficacy of the company's lead therapeutic candidate and contributed to the stock's sharp decline.
2. Significant Workforce Reduction and Restructuring. On June 15, 2026, enGene announced a strategic decision to reduce its workforce by approximately 50% to streamline operations and preserve cash. This drastic measure, intended to align resources with core strategic goals, signals underlying financial pressures within the company. The restructuring is projected to incur estimated costs of $5.7 million to $6.4 million, along with an additional $4.7 million to $5.0 million in non-cash stock-based compensation expense primarily due to accelerated vesting of stock options.
Show more
enGene Therapeutics (ENGN) stock has lost about 70% since 3/31/2026 because of the following key factors:
1. Disappointing 12-Month Durability Data from LEGEND Trial. enGene Therapeutics announced updated interim results from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid on May 7, 2026. While initial complete response (CR) rates were reported at 54% at any time and 43% at six months, the crucial Kaplan-Meier estimate for the 12-month CR rate was only 25%. This significantly lower durability outcome, which the CEO acknowledged was "not what we hoped," raised substantial concerns among investors regarding the long-term efficacy of the company's lead therapeutic candidate and contributed to the stock's sharp decline.
2. Significant Workforce Reduction and Restructuring. On June 15, 2026, enGene announced a strategic decision to reduce its workforce by approximately 50% to streamline operations and preserve cash. This drastic measure, intended to align resources with core strategic goals, signals underlying financial pressures within the company. The restructuring is projected to incur estimated costs of $5.7 million to $6.4 million, along with an additional $4.7 million to $5.0 million in non-cash stock-based compensation expense primarily due to accelerated vesting of stock options.
Show more
Updated on 7/1/2026
enGene Therapeutics (ENGN) stock has lost about 70% since 3/31/2026 because of the following key factors:
1. Disappointing 12-Month Durability Data from LEGEND Trial. enGene Therapeutics announced updated interim results from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid on May 7, 2026. While initial complete response (CR) rates were reported at 54% at any time and 43% at six months, the crucial Kaplan-Meier estimate for the 12-month CR rate was only 25%. This significantly lower durability outcome, which the CEO acknowledged was "not what we hoped," raised substantial concerns among investors regarding the long-term efficacy of the company's lead therapeutic candidate and contributed to the stock's sharp decline.
2. Significant Workforce Reduction and Restructuring. On June 15, 2026, enGene announced a strategic decision to reduce its workforce by approximately 50% to streamline operations and preserve cash. This drastic measure, intended to align resources with core strategic goals, signals underlying financial pressures within the company. The restructuring is projected to incur estimated costs of $5.7 million to $6.4 million, along with an additional $4.7 million to $5.0 million in non-cash stock-based compensation expense primarily due to accelerated vesting of stock options.
3. Widening Net Loss in Fiscal Q2 2026 Driven by Increased Operating Expenses. For the fiscal second quarter ended April 30, 2026, enGene reported a net loss of $30.2 million, or $0.43 per share. This represented a wider loss compared to the $25.8 million net loss reported in fiscal Q2 2025. Total operating expenses for fiscal Q2 2026 increased to $32.0 million from $27.1 million year-over-year, largely due to higher personnel and clinical costs associated with the LEGEND trial and preparations for regulatory submissions. Despite beating analyst EPS estimates, the year-over-year increase in net loss and operating expenses highlighted growing financial strain.
4. Analyst Downgrade Following Clinical and Corporate Updates. In response to the disappointing durability data from the LEGEND trial and the subsequent workforce reduction, analyst sentiment turned negative. For example, Morgan Stanley downgraded enGene's stock to Underweight from Equalweight, specifically noting that "Detalimogene's durability profile 'Not Competitive'." This explicit linkage between the clinical trial results, corporate actions, and analyst ratings further exacerbated investor concerns and contributed to the stock's significant decline.
Show less
enGene Therapeutics (ENGN) stock has lost about 70% since 3/31/2026 because of the following key factors:
1. Disappointing 12-Month Durability Data from LEGEND Trial. enGene Therapeutics announced updated interim results from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid on May 7, 2026. While initial complete response (CR) rates were reported at 54% at any time and 43% at six months, the crucial Kaplan-Meier estimate for the 12-month CR rate was only 25%. This significantly lower durability outcome, which the CEO acknowledged was "not what we hoped," raised substantial concerns among investors regarding the long-term efficacy of the company's lead therapeutic candidate and contributed to the stock's sharp decline.
2. Significant Workforce Reduction and Restructuring. On June 15, 2026, enGene announced a strategic decision to reduce its workforce by approximately 50% to streamline operations and preserve cash. This drastic measure, intended to align resources with core strategic goals, signals underlying financial pressures within the company. The restructuring is projected to incur estimated costs of $5.7 million to $6.4 million, along with an additional $4.7 million to $5.0 million in non-cash stock-based compensation expense primarily due to accelerated vesting of stock options.
3. Widening Net Loss in Fiscal Q2 2026 Driven by Increased Operating Expenses. For the fiscal second quarter ended April 30, 2026, enGene reported a net loss of $30.2 million, or $0.43 per share. This represented a wider loss compared to the $25.8 million net loss reported in fiscal Q2 2025. Total operating expenses for fiscal Q2 2026 increased to $32.0 million from $27.1 million year-over-year, largely due to higher personnel and clinical costs associated with the LEGEND trial and preparations for regulatory submissions. Despite beating analyst EPS estimates, the year-over-year increase in net loss and operating expenses highlighted growing financial strain.
4. Analyst Downgrade Following Clinical and Corporate Updates. In response to the disappointing durability data from the LEGEND trial and the subsequent workforce reduction, analyst sentiment turned negative. For example, Morgan Stanley downgraded enGene's stock to Underweight from Equalweight, specifically noting that "Detalimogene's durability profile 'Not Competitive'." This explicit linkage between the clinical trial results, corporate actions, and analyst ratings further exacerbated investor concerns and contributed to the stock's significant decline.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -72.1% change in ENGN stock from 3/31/2026 to 7/12/2026 was primarily driven by a -3.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312026 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.81 | 1.90 | -72.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 67 | 70 | -3.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/12/2026| Return | Correlation | |
|---|---|---|
| ENGN | -72.1% | |
| Market (SPY) | 16.1% | 23.1% |
| Sector (XLV) | 9.7% | 8.3% |
Fundamental Drivers
The -79.0% change in ENGN stock from 12/31/2025 to 7/12/2026 was primarily driven by a -26.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.03 | 1.90 | -79.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 51 | 70 | -26.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| ENGN | -79.0% | |
| Market (SPY) | 11.0% | 22.7% |
| Sector (XLV) | 4.3% | 9.3% |
Fundamental Drivers
The -47.8% change in ENGN stock from 6/30/2025 to 7/12/2026 was primarily driven by a -26.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.64 | 1.90 | -47.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 51 | 70 | -26.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| ENGN | -47.8% | |
| Market (SPY) | 23.2% | 23.6% |
| Sector (XLV) | 20.9% | 14.2% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/12/2026| Return | Correlation | |
|---|---|---|
| ENGN | ||
| Market (SPY) | 76.3% | 9.2% |
| Sector (XLV) | 26.9% | 8.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ENGN Return | - | - | -54% | -28% | 36% | -79% | -90% |
| Peers Return | -51% | -42% | 14% | -1% | 194% | 102% | 91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| ENGN Win Rate | - | - | 50% | 42% | 58% | 57% | |
| Peers Win Rate | 33% | 48% | 50% | 38% | 58% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| ENGN Max Drawdown | - | - | - | -71% | -64% | -88% | |
| Peers Max Drawdown | -71% | -68% | -64% | -70% | -57% | -35% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CGON, IBRX, URGN, RLMD, TARA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/10/2026 (YTD)
How Low Can It Go
| Event | ENGN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -56.3% | -18.8% |
| % Gain to Breakeven | 128.8% | 23.1% |
| Time to Breakeven | 128 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -41.0% | -7.8% |
| % Gain to Breakeven | 69.5% | 8.5% |
| Time to Breakeven | 59 days | 18 days |
In The Past
enGene Therapeutics's stock fell -56.3% during the 2025 US Tariff Shock. Such a loss loss requires a 128.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ENGN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -56.3% | -18.8% |
| % Gain to Breakeven | 128.8% | 23.1% |
| Time to Breakeven | 128 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -41.0% | -7.8% |
| % Gain to Breakeven | 69.5% | 8.5% |
| Time to Breakeven | 59 days | 18 days |
In The Past
enGene Therapeutics's stock fell -56.3% during the 2025 US Tariff Shock. Such a loss loss requires a 128.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About enGene Therapeutics (ENGN)
AI Analysis | Feedback
Like Moderna or BioNTech, but applying genetic technology to develop gene-based treatments for cancer rather than vaccines.
The Tesla of gene therapy delivery, focused on developing a novel non-viral method to get genetic instructions into cancer cells.
AI Analysis | Feedback
- EG-70: A non-viral gene therapy designed to deliver interferon alpha 2b (IFNα2b) DNA directly into the bladder for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG.
AI Analysis | Feedback
enGene Therapeutics (ENGN) is a clinical-stage biotechnology company focused on developing gene therapies for oncology and immunology. As a company in the research and development phase, enGene Therapeutics does not currently have major customers in the traditional sense of selling products or services to other companies or individuals.
Their primary activities involve advancing their pipeline of drug candidates through preclinical and clinical trials. Revenue generation at this stage typically comes from financing activities (e.g., equity investments), grants, and potential future collaborations or licensing agreements with larger pharmaceutical companies, rather than from direct sales of commercialized products.
Therefore, enGene Therapeutics does not have identifiable major customers at this time.
AI Analysis | Feedback
null
AI Analysis | Feedback
Ron Cooper, Chief Executive Officer
Ron Cooper has served as enGene Therapeutics' CEO and a member of its Board of Directors since July 2024. Previously, Mr. Cooper was President and Chief Executive Officer of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that was acquired by Ipsen for up to $1.2 billion in March 2023. While at Albireo Pharma, he took the company public, created a new corporate strategy, guided Bylvay® through three Phase III programs, regulatory approvals, and a global commercial launch, and raised over $850 million of capital. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers Squibb (BMS) in various roles, most recently as President, Europe, where he played a leadership role in several successful product launches. He currently serves as Chairman of the Board for C4 Therapeutics and a member of the Board of Directors of Generation Bio.
Ryan Daws, Chief Financial Officer
Ryan Daws has served as enGene's Chief Financial Officer and Head of Business Development since November 27, 2023. Prior to joining enGene, Mr. Daws was Chief Financial Officer and Head of Business Development at Obsidian Therapeutics, Inc. from July 2019 to November 2023. From June 2017 to March 2019, he was a Managing Director in the Healthcare Investment Banking Group at Robert W. Baird & Co., focusing on life sciences companies. Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals, Inc. from January 2014 to June 2017. He spent nearly 15 years originating and executing equity and mergers and acquisitions transactions in the life sciences sector at Cowen and Company, LLC and Stifel, Nicolaus & Co Inc.
Anthony T. Cheung, PhD, Co-Founder & Chief Scientific Officer
Anthony T. Cheung is a Co-Founder and the Chief Scientific Officer of enGene Therapeutics.
Matthew Boyd, Chief Regulatory Officer
Matthew Boyd was promoted to Chief Regulatory Officer in July 2025, having previously served as Senior Vice President, Regulatory Affairs. He has over 25 years of regulatory experience and has led the submission of numerous drug applications, including the approval of Bylvay for a rare pediatric liver disease while at Albireo Pharma.
Jill Buck, Chief Development Officer
Jill Buck was promoted to Chief Development Officer in July 2025, from her previous role as Senior Vice President, Clinical Development Operations. She has more than 25 years of global drug development experience across multiple therapeutic areas.
Ron Cooper has served as enGene Therapeutics' CEO and a member of its Board of Directors since July 2024. Previously, Mr. Cooper was President and Chief Executive Officer of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that was acquired by Ipsen for up to $1.2 billion in March 2023. While at Albireo Pharma, he took the company public, created a new corporate strategy, guided Bylvay® through three Phase III programs, regulatory approvals, and a global commercial launch, and raised over $850 million of capital. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers Squibb (BMS) in various roles, most recently as President, Europe, where he played a leadership role in several successful product launches. He currently serves as Chairman of the Board for C4 Therapeutics and a member of the Board of Directors of Generation Bio.
Ryan Daws, Chief Financial Officer
Ryan Daws has served as enGene's Chief Financial Officer and Head of Business Development since November 27, 2023. Prior to joining enGene, Mr. Daws was Chief Financial Officer and Head of Business Development at Obsidian Therapeutics, Inc. from July 2019 to November 2023. From June 2017 to March 2019, he was a Managing Director in the Healthcare Investment Banking Group at Robert W. Baird & Co., focusing on life sciences companies. Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals, Inc. from January 2014 to June 2017. He spent nearly 15 years originating and executing equity and mergers and acquisitions transactions in the life sciences sector at Cowen and Company, LLC and Stifel, Nicolaus & Co Inc.
Anthony T. Cheung, PhD, Co-Founder & Chief Scientific Officer
Anthony T. Cheung is a Co-Founder and the Chief Scientific Officer of enGene Therapeutics.
Matthew Boyd, Chief Regulatory Officer
Matthew Boyd was promoted to Chief Regulatory Officer in July 2025, having previously served as Senior Vice President, Regulatory Affairs. He has over 25 years of regulatory experience and has led the submission of numerous drug applications, including the approval of Bylvay for a rare pediatric liver disease while at Albireo Pharma.
Jill Buck, Chief Development Officer
Jill Buck was promoted to Chief Development Officer in July 2025, from her previous role as Senior Vice President, Clinical Development Operations. She has more than 25 years of global drug development experience across multiple therapeutic areas.
AI Analysis | Feedback
Key Risks to enGene Therapeutics (ENGN)
- High Dependence on Lead Product Candidate: enGene Therapeutics' business success is highly dependent on the successful clinical development, regulatory approval, and commercialization of its lead product candidate, detalimogene voraplasmid (previously EG-70), for non-muscle invasive bladder cancer. The investment thesis for enGene "hinges on positive LEGEND trial results", and its pipeline is "focused almost entirely on one catalyst". Failure of this single asset would significantly impact the company's prospects.
- Inability to Achieve Profitability and Significant Cash Burn: enGene is a clinical-stage biotechnology company that has consistently incurred net losses since its inception and has not generated any revenue from product sales to date. The company is not forecast to become profitable over the next three years, and its ongoing research and development expenses are expected to increase, leading to substantial ongoing cash burn. This poses significant financial sustainability risks.
- Clinical Development, Regulatory, and Market Access Challenges: As a biotechnology company, enGene faces inherent operational challenges in clinical development, including the rigorous demands of clinical trials and the complex regulatory landscape for gene therapies. Obtaining positive trial data and securing regulatory approval on anticipated timelines are critical. Beyond approval, the company also faces risks related to competition, reimbursement challenges, and pricing pressures for gene therapies in the market.
AI Analysis | Feedback
null
AI Analysis | Feedback
enGene Therapeutics (Nasdaq: ENGN) focuses on genetic medicines, with its primary product being detalimogene voraplasmid (formerly EG-70). This therapy targets high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
The addressable market for high-risk non-muscle invasive bladder cancer (NMIBC) in the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately USD 1.60 billion in 2023. This segment is directly relevant to enGene's lead product. While the broader non-muscle invasive bladder cancer (NMIBC) market in these seven major markets was estimated to be around USD 3 billion in 2025, with the United States accounting for nearly 65% of that market, enGene's therapy specifically targets the high-risk, BCG-unresponsive population.
AI Analysis | Feedback
enGene Therapeutics (Nasdaq: ENGN) is a clinical-stage biotechnology company focused on developing genetic medicines, primarily utilizing its proprietary Dually Derivatized Oligochitosan (DDX) platform for localized delivery of therapeutics to mucosal tissues and other organs.
The company's future revenue growth over the next 2-3 years is expected to be driven by the following factors:
- Regulatory Approval and Commercial Launch of Detalimogene: enGene's lead product candidate, detalimogene voraplasmid (also known as EG-70), for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), is a key revenue driver. The company plans a Biologics License Application (BLA) submission for detalimogene in the second half of 2026, with a potential approval anticipated in 2027. This represents the company's first potential commercial product and a significant entry into the NMIBC market.
- Market Penetration and Adoption of Detalimogene: Following potential approval, a primary driver will be the successful market penetration and adoption of detalimogene within its initial indication of high-risk, BCG-unresponsive NMIBC with CIS. enGene believes detalimogene has the potential to become a "first choice therapy" in this patient population, which has a high clinical burden and unmet medical needs.
- Expansion of Detalimogene's Label or Use Cases: Beyond its initial indication, enGene anticipates that detalimogene's profile could support its potential for first-line use in patients with high-risk, BCG-unresponsive NMIBC with CIS. The company's CEO has also suggested that the broader bladder cancer market is projected to grow significantly with the introduction of new products, implying potential for expanded applications or use in earlier lines of therapy, which could further drive revenue within the 2-3 year timeframe if supported by additional data and regulatory approvals.
- Advancement and Partnerships for DDX Platform-Derived Candidates: enGene's proprietary DDX platform is designed for delivering genetic medicines to various mucosal tissues and organs, including genitourinary cancers and the lung. While specific new product launches from the platform might extend beyond the immediate 2-3 year horizon, the advancement of other pipeline candidates utilizing this platform or strategic partnerships leveraging the DDX technology could generate upfront payments, milestone revenues, or future product sales within this timeframe.
AI Analysis | Feedback
Share Issuance
- In November 2025, enGene Therapeutics successfully closed an underwritten public offering of its common shares and pre-funded warrants.
- This public offering resulted in net proceeds of $140.1 million.
Inbound Investments
- In October 2024, the company expected to receive CAD 60.148968 million in funding from a group of investors.
- In January 2026, the Company expanded its existing loan and security agreement with Hercules Capital, Inc.
Capital Expenditures
- While specific dollar amounts for capital expenditures are not separately detailed in available summaries, enGene Therapeutics expects its cash and marketable securities to fund operating expenses, debt obligations, and capital expenditures into the second half of 2028, following a November 2025 public offering.
- The company's cash and marketable securities as of October 31, 2024, and April 30, 2025, were anticipated to fund operating expenses, debt obligations, and capital expenditures into 2027.
- Increased research and development expenses in 2025, rising by $56.2 million compared to 2024, were primarily driven by increased manufacturing, personnel, and clinical costs related to the LEGEND trial and preparation for the planned Biologics License Application (BLA) submission.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.32 |
| Mkt Cap | 1.2 |
| Rev LTM | 3 |
| Op Inc LTM | -120 |
| FCF LTM | -136 |
| FCF 3Y Avg | -88 |
| CFO LTM | -135 |
| CFO 3Y Avg | -88 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 351.5% |
| Rev Chg 3Y Avg | 1,771.2% |
| Rev Chg Q | 167.6% |
| QoQ Delta Rev Chg LTM | 25.5% |
| Op Inc Chg LTM | -18.2% |
| Op Inc Chg 3Y Avg | -14.6% |
| Op Mgn LTM | -185.4% |
| Op Mgn 3Y Avg | -12,397.7% |
| QoQ Delta Op Mgn LTM | 40.6% |
| CFO/Rev LTM | -208.8% |
| CFO/Rev 3Y Avg | -9,119.3% |
| FCF/Rev LTM | -212.3% |
| FCF/Rev 3Y Avg | -9,134.9% |
Segment Financials
Revenue by Segment| $ Mil | 2022 | 2021 | 2020 |
|---|---|---|---|
| Developing genetic medicines to improve the lives of patients suffering from bladder cancer | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |
| $ Mil | 2020 |
|---|---|
| Developing genetic medicines to improve the lives of patients suffering from bladder cancer | -14 |
| Total | -14 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Developing genetic medicines to improve the lives of patients suffering from bladder cancer | -117 | -55 |
| Total | -117 | -55 |
| $ Mil | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Developing genetic medicines to improve the lives of patients suffering from bladder cancer | 311 | 87 | 24 | 15 |
| Total | 311 | 87 | 24 | 15 |
Price Behavior
Price Behavior
| Market Price | $1.90 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 11/01/2023 | |
| Distance from 52W High | -84.4% | |
| 50 Days | 200 Days | |
| DMA Price | $2.46 | $6.83 |
| DMA Trend | down | down |
| Distance from DMA | -22.7% | -72.2% |
| 3M | 1YR | |
| Volatility | 182.9% | 123.2% |
| Downside Capture | 1246.17 | 454.83 |
| Upside Capture | 245.52 | 287.61 |
| Correlation (SPY) | 23.8% | 23.8% |
ENGN Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.67 | 3.58 | 3.13 | 2.19 | 2.27 | 0.12 |
| Up Beta | 3.46 | 3.64 | 2.53 | 2.30 | 1.19 | 0.14 |
| Down Beta | 1.87 | -3.43 | -1.48 | -0.30 | 1.11 | -0.36 |
| Up Capture | 76% | 377% | 280% | 212% | 682% | 45% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 9 | 19 | 30 | 59 | 122 | 308 |
| Down Capture | 134% | 735% | 650% | 290% | 200% | 112% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 12 | 22 | 33 | 65 | 126 | 343 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENGN | |
|---|---|---|---|---|
| ENGN | -50.5% | 122.9% | 0.40 | - |
| Sector ETF (XLV) | 20.3% | 15.7% | 0.98 | 14.6% |
| Equity (SPY) | 22.1% | 12.5% | 1.31 | 23.7% |
| Gold (GLD) | 23.5% | 27.8% | 0.75 | 9.0% |
| Commodities (DBC) | 23.6% | 18.7% | 0.99 | -6.3% |
| Real Estate (VNQ) | 13.4% | 13.9% | 0.67 | 10.9% |
| Bitcoin (BTCUSD) | -42.5% | 42.8% | -1.17 | 18.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENGN | |
|---|---|---|---|---|
| ENGN | -37.8% | 131.1% | -0.01 | - |
| Sector ETF (XLV) | 6.5% | 14.9% | 0.25 | 8.4% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 9.3% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 2.0% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | -2.0% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 2.2% |
| Bitcoin (BTCUSD) | 13.8% | 53.4% | 0.44 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENGN | |
|---|---|---|---|---|
| ENGN | -21.1% | 131.1% | -0.01 | - |
| Sector ETF (XLV) | 10.3% | 16.6% | 0.51 | 8.4% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 9.3% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 2.0% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | -2.0% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 2.2% |
| Bitcoin (BTCUSD) | 58.6% | 66.2% | 0.99 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/25/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 6/15/2026 | 9.3% | 4.3% | |
| 3/9/2026 | -18.8% | -17.5% | -15.6% |
| 12/22/2025 | 5.1% | 2.1% | 38.8% |
| 9/11/2025 | -5.8% | 14.9% | 38.4% |
| 6/12/2025 | 0.9% | 2.2% | 9.0% |
| 3/10/2025 | -1.7% | -2.1% | -21.4% |
| 12/19/2024 | -2.2% | 7.7% | 22.3% |
| 9/10/2024 | 3.1% | 6.8% | 6.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 7 | 5 |
| # Negative | 5 | 3 | 4 |
| Median Positive | 3.1% | 6.2% | 22.3% |
| Median Negative | -5.8% | -10.0% | -12.7% |
| Max Positive | 9.3% | 14.9% | 38.8% |
| Max Negative | -18.8% | -17.5% | -21.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 6/15/2026 | 9.3% | 4.3% | |
| 3/9/2026 | -18.8% | -17.5% | -15.6% |
| 12/22/2025 | 5.1% | 2.1% | 38.8% |
| 9/11/2025 | -5.8% | 14.9% | 38.4% |
| 6/12/2025 | 0.9% | 2.2% | 9.0% |
| 3/10/2025 | -1.7% | -2.1% | -21.4% |
| 12/19/2024 | -2.2% | 7.7% | 22.3% |
| 9/10/2024 | 3.1% | 6.8% | 6.5% |
| 6/14/2024 | -10.0% | -10.0% | -9.9% |
| 3/11/2024 | 1.6% | 6.2% | -4.7% |
| SUMMARY STATS | |||
| # Positive | 5 | 7 | 5 |
| # Negative | 5 | 3 | 4 |
| Median Positive | 3.1% | 6.2% | 22.3% |
| Median Negative | -5.8% | -10.0% | -12.7% |
| Max Positive | 9.3% | 14.9% | 38.8% |
| Max Negative | -18.8% | -17.5% | -21.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/15/2026 | 10-Q |
| 01/31/2026 | 03/09/2026 | 10-Q |
| 10/31/2025 | 12/22/2025 | 10-K |
| 07/31/2025 | 09/11/2025 | 10-Q |
| 04/30/2025 | 06/12/2025 | 10-Q |
| 01/31/2025 | 03/10/2025 | 10-Q |
| 10/31/2024 | 12/19/2024 | 10-K |
| 07/31/2024 | 09/10/2024 | 10-Q |
| 04/30/2024 | 06/14/2024 | 10-Q |
| 01/31/2024 | 03/11/2024 | 10-Q |
| 10/31/2023 | 01/29/2024 | 10-K |
| 07/31/2023 | 09/26/2023 | S-4/A |
| 04/30/2023 | 08/09/2023 | S-4 |
| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/15/2026 | 10-Q |
| 01/31/2026 | 03/09/2026 | 10-Q |
| 10/31/2025 | 12/22/2025 | 10-K |
| 07/31/2025 | 09/11/2025 | 10-Q |
| 04/30/2025 | 06/12/2025 | 10-Q |
| 01/31/2025 | 03/10/2025 | 10-Q |
| 10/31/2024 | 12/19/2024 | 10-K |
| 07/31/2024 | 09/10/2024 | 10-Q |
| 04/30/2024 | 06/14/2024 | 10-Q |
| 01/31/2024 | 03/11/2024 | 10-Q |
| 10/31/2023 | 01/29/2024 | 10-K |
| 07/31/2023 | 09/26/2023 | S-4/A |
| 04/30/2023 | 08/09/2023 | S-4 |
Recent Forward Guidance
Updated 7/12/2026Latest: Q2 2026 Earnings Reported 6/15/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 BLA Filing Initiation | |||||||
| 2027 Commercial Launch | |||||||
Prior: Q1 2026 Earnings Reported 3/9/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | 2,028 | ||||||
Q4 2025 Earnings Reported 12/22/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 BLA Submission | |||||||
| 2026 LEGEND Trial Data Update | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/12/2026